I am very happy to have bought and held a substantial number of these shares since early 2016 at an average price of less than 100p. The latest news from the company about Lukozor is good. You can make money here as a dealer, but for me this was and still is a
gamble on Lukozor.
is please can I have the 12,000 shares I've sold between 80 p and 160p back.. I've only 3000 left to sell now.. yikes..
The market cap you're talk about off the back of the future s/p target numbers you quote is incredible to me .. especially, are you sutre about 877p ? (It's now the guts of a quarter of a billion mc.. that factorial is a big big big number indeed...)
<b>ImmuPharma PLC 40.2% Potential Upside Indicated by finnCap
Posted by: Amilia Stone 12th December 2017</b>
ImmuPharma PLC using EPIC/TICKER code (LON:IMM) a pharmaceutical company focusing on developing novel medicines with high sales potential has had its stock rating noted as Initiates/Starts with the recommendation being set at BUY this morning by analysts at finnCap. ImmuPharma PLC are listed in the Health Care sector within AIM. finnCap have set a target price of 237 GBX on its stock. This indicates the analyst now believes there is a potential upside of 40.2% from the opening price of 169 GBX. Over the last 30 and 90 trading days the company share price has increased 71 points and increased 121.75 points respectively. The 52 week high for the stock is 171.75 GBX while the 52 week low for the stock is 36 GBX.
ImmuPharma PLC has a 50 day moving average of 105.55 GBX and a 200 Day Moving Average share price is recorded at . There are currently 129,665,818 shares in issue with the average daily volume traded being 360,049. Market capitalisation for LON:IMM is £222,340,888 GBP.
And i'm still selling down by increment but am alas down to a third of my original holding now .. and having started selling way before 100p - less than 80 p from memory - it is now occurring to me that I may well end up having under sold my holding considerably - aka massively - here.. still eveyone is wiser with the benefit of hindight and pharma is an area that I'm relatively new to betting on and so I live and learn for when such situations come again ( hopefully with Futura or Midatech for eg )
PS; As we're still at phase 3 here - although it looks like that will now be successful and they maybe get a fast track licence path - this may well go much higher again from here .. I guess.. unless issue(s) come out in final testing results .... probably unlikely that now, I'd guess..
Still, very - very - thankful for this... and still a fair few thousand left to sell..and will keep doing that by increment on further strength , hopefully
I've stopped selling now Chrissp.. but that's perhaps 'for now' instead of 'now' though.. I'd think about selling a little more at 115p if it were to go there.. obviously if in a years time this is approved and on the market then it would be a lot higher s/p than this.. how high I don't have a clue..also there has got to be a decent chance of some sort of a deal / buy out with a bigger player... although they may go it on their own too..
It's approaching 150m market cap already I see....so perhaps multi baggering from here is a big ask...
Nice to Michu - interesting that you have sold some of your holding. I am keeping all mine that I have accumulated over many years at an average of 62P. This is the first time that I am showing a gain.
I am amazed that they have jumped by nearly 20% this morning with no comment from the company.
maybe it's buy and hold institutional money coming in here..
I sold another 10% at 100p just now.. maybe I shouldnt be selling at all .. only time will tell .. still have a decent chunk left though and my average is 50 ish p..
surprising and nice...
please keep going up ...
Seems some serious money is doing some stake building here today.. question is how big a stake are they building and are the traders or buy and holders etc.... and thats a guesssing game...
I'm thankful to have done very nicely here so far but I still have high hopes fro here .. however I sold 15% of my holding near end of today as I've seen two quick big rise occurrances like this since i've been involved and both were followed by good subsequent falls, in due course.. However, we're getting close to phase 3 results and hopefully allotment of slot on super fast approval process - 6 months ish I think from RNS memory - and so it could be very diffeerent this time (hopefully)
Effectively a one trick pony though which is always tricky :-).. but that one trick might be a hell of a trick.
Immupharma caught my attention two years ago. I have a substantial holding below the current price.
The main development is the Lupus drug now in its final stage of testing. They are also developing a number of other drugs.
and having bought small in 30's and 40's p I am continuing to build a position out slowly here. I'm very comfortable buying in 50's, not least because I'm well up on current position but also because I see 80p as a realistic target in coming months and much more if this drug gets final approval.
But its a one trick pony type stock and so if poor results from phase III testing then huge ouch.. but side effects seem not to be an issue and so I see plenty of time/room for this to appreciate in 2017 ahead of Jan 2018 detailed testing results.
"ImmuPharma has announced that it has been invited to open an additional site in Mauritius as part of its Phase III clinical trial of Lupuzor, its lead programme for the treatment of auto-immune disease Lupus. Up to 30 lupus patients are reportedly ready for enrolment these will comprise part of the original 200 patients expected to be recruited for the Phase III trial in a country where the relative incidence of the disease is high. Todays news further illustrates, in our view, the continued lack of affordable and effective treatments for the disease, reflecting demand which is global in nature."
Two notes out this morning (both on research tree):
"Last week, ImmuPharma hosted a symposium featuring Prof Sylviane Muller, the inventor of Lupuzor, detailing the discovery, mechanism of action and wider opportunity for the use of Lupuzor in the treatment of Lupus and a variety of other autoimmune indications. A presentation from the event can be viewed online and offers investors a chance to look further into the detail of the molecule which, while by no means ImmuPharmas only development programme, is clearly the most important near-term value driver for the business."
"Last week we attended a symposium hosted by ImmuPharma on LupuzorTM, the company's lead compound for the potential treatment of Lupus, a chronic auto-immune disease, currently in a pivotal Phase III trial. The event was led by Prof. Sylviane Muller, the inventor of LupuzorTM, who presented on the unique mechanisms of action of the drug. Prof. Muller recently received 'The CNRS Medal of Innovation' for her discoveries made on LupuzorTM. The symposium provided a good overview of the mechanisms of action of LupuzorTM. Also of particular interest, was the evidence provided on the further potential uses of the drug in other major disease indications, including Rheumatoid Arthritis, Crohns Disease, and Asthma."
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.